Compare FCPT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | VERA |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2015 | 2021 |
| Metric | FCPT | VERA |
|---|---|---|
| Price | $23.62 | $40.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $27.83 | ★ $81.30 |
| AVG Volume (30 Days) | 546.1K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.23% | N/A |
| EPS Growth | ★ 1.87 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $294,132,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | $7.93 | $416.83 |
| P/E Ratio | $21.60 | ★ N/A |
| Revenue Growth | ★ 9.72 | N/A |
| 52 Week Low | $22.78 | $18.53 |
| 52 Week High | $28.98 | $56.05 |
| Indicator | FCPT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 50.06 |
| Support Level | $22.87 | $37.36 |
| Resistance Level | $23.66 | $42.73 |
| Average True Range (ATR) | 0.42 | 2.02 |
| MACD | -0.16 | 0.19 |
| Stochastic Oscillator | 6.22 | 57.25 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.